Compare CVS Health Corp (CVS) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs QUALCOMM, Inc. — how do they compare? CVS Health Corp trades at $93.43 (market cap $122.36B), while QUALCOMM, Inc. trades at $162.7 (market cap $170.28B). The key difference: QUALCOMM, Inc. is the larger of the two by market cap, and CVS Health Corp pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| CVS | QCOM | |
|---|---|---|
Market Cap | $122.36B | $170.28B |
Sector | Health | Technology |
52-Week High | $110.60 | $251.10 |
52-Week Low | $64.88 | $124.07 |
Enterprise Value | $184.71B | $177.24B |
Dividend Yield | 2.78% | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
Qualcomm (QCOM) trades at $167.86, up 4.66% with strong recent earnings performance despite a Q2 2026 miss. The stock shows bullish technical signals with solid fundamentals including $44.28B revenue and 21.01% net margin. Recent news highlights Qualcomm's AI and automotive diversification efforts, though competition from Nvidia's PC chip entry poses challenges. Analyst consensus targets $200.56 with 42.65% buy ratings.
Qualcomm presents a balanced opportunity with strong cash flow generation and strategic diversification into AI/data centers offsetting smartphone market softness. Key risks include margin pressures and intensified competition. The current valuation at 19.18 P/E appears reasonable given growth initiatives, supporting a cautiously optimistic outlook for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
